Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
Virol Sin. 2013 Apr;28(2):71-80. doi: 10.1007/s12250-013-3313-x. Epub 2013 Apr 11.
More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.
已有超过 40 种单克隆抗体（mAbs）被批准用于多种疾病适应症，其中只有一种（Synagis）用于病毒疾病，不是用于治疗，而是用于预防。然而，在过去十年中，已经发现并表征了新型强效 mAbs，它们具有作为治疗剂对抗对公共卫生和生物安全具有重要意义的病毒的潜力，包括亨德拉病毒（HeV）、尼帕病毒（NiV）、严重急性呼吸综合征冠状病毒（SARS-CoV）、埃博拉病毒（EBOV）、西尼罗河病毒（WNV）、流感病毒（IFV）和人类免疫缺陷病毒 1 型（HIV-1）。在这里，我们重点介绍具有人类来源的抗体的此类 mAbs，并强调最近的结果以及与其作为治疗剂的潜力相关的技术和机制。
